Despite their effectiveness, only 40% of patients respond to the first antidepressant they try. A recent article strongly suggests that a particular protein, GPR56, is involved in the biology of depression and the effect of antidepressants. The research team believes that this protein could offer a novel target for new antidepressant drugs.